



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 587 659 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
07.05.1997 Bulletin 1997/19

(51) Int. Cl.<sup>6</sup>: A61K 9/51, A61K 9/50,  
A61K 47/28

(21) Application number: 92911403.1

(86) International application number:  
PCT/SE92/00367

(22) Date of filing: 01.06.1992

(87) International publication number:  
WO 92/21331 (10.12.1992 Gazette 1992/31)

### (54) PHARMACEUTICAL CARRIER

PHARMAZETISCHER TRÄGER

EXCIPIENTS PHARMACEUTIQUES

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI LU MC NL  
SE

(74) Representative: Percy, Richard Keith et al  
Patents Department  
British Technology Group Ltd  
101 Newington Causeway  
London SE1 6BU (GB)

(30) Priority: 31.05.1991 SE 9101665

(56) References cited:  
EP-A- 0 231 039 EP-A- 0 415 794

(43) Date of publication of application:  
23.03.1994 Bulletin 1994/12

- Biotechnology and Applied Biochemistry, Vol. 10, 1988, KARIN LOVGREN et al.: "The requirement of lipids for the formation of immunostimulating complexes (iscoms)", see page 161 - page 172.
- Biochimica et Biophysica Acta, Vol. 1062, 1991, GIDEON F.A. KERSTEN et al.: "On the structure of immune-stimulating saponin-lipid complexes (iscoms)" see pp. 165-171

(73) Proprietor: BRITISH TECHNOLOGY GROUP  
LIMITED  
London SE1 6BU (GB)

(72) Inventors:  
• MOREIN, Bror  
S-755 91 Uppsala (SE)  
• LÖVGREN, Karin  
S-752 40 Uppsala (SE)

EP 0 587 659 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

The present invention relates to the use of nano particles as pharmaceutical carriers, and pharmaceutical compositions containing said particles.

5 The use of colloidal particles of micrometer size as pharmaceutical carriers in different forms of administration has been the object of many investigations during the last decades. Lately, one has also succeeded in producing nano particulate carriers and demonstrated that they have large possibilities to facilitate the uptake of incorporated drugs.

In intravenous administration of colloidal particles they will be retrieved in different organs depending on the size and surface characteristics of the particles. Particles having a diameter larger than 7  $\mu\text{m}$  are normally caught by the 10 lung capillaries. Particles of the size 100 nm - 5  $\mu\text{m}$  are effectively eliminated by the reticuloendothelial system (RES), principally by the liver. This is a very fast process which normally gives the particles in the blood a half-life shorter than 15 1 minute. The rate of elimination can be strongly reduced if the surface of the particles is modified by being coated with substances making it hydrophilic.

Particles being smaller than 100 nm can theoretically, if they are not quickly eliminated by RES, leave the systemic 20 circulation through gaps in the endothelium lining the inside of the blood vessels. Said gaps are of different size in different capillary beds. The endothelium in the pancreas, intestines and kidneys thus has gaps of 50-60 nm while the endothelium of the liver, spleen and bone marrow has gaps of about 100 nm. The blood vessels in certain tumours are also believed to have a more permeable endothelium allowing particles of nano size to pass into the tumour tissue. It has also recently been discovered that nano particles can penetrate the mucous membrane of the intestines, which 25 should facilitate good absorption after oral administration of drugs which are sparingly soluble.

Pharmaceutical carriers in the form of injectable nano particles have therefore been of great interest, especially for the administration of drugs to tumours, and for sustained release of drugs and for the possibility of affecting the distribution in the body of the drug after intravenous injection.

Although many different materials have been investigated with respect to the use as a matrix material for particulate 25 pharmaceutical carriers there are only a few which have turned out to be of use for particles of nanometer size, i.e. certain liposomes, lipoproteins, especially Low Density Lipoproteins (LDL), and a few polymeric material, primarily poly-alkylcyanoacrylate.

The use of said known nano particulate carriers is however associated with many problems. Liposomes are quickly 30 eliminated by RES and are in addition fragile which brings about liposome formulations which are instable and hard to handle. LDL is an article in short supply which is extracted from blood. in addition only very hydrophobic drugs can be incorporated without a first transformation into prodrugs. Polymeric pharmaceutical carriers are quickly eliminated by the RES and are in addition obtained in a broad size distribution which makes the control of the release of incorporated drugs more difficult.

Morein et al describe in WO 90103184 an iscom-matrix consisting of a complex between at least one lipid, such a 35 cholesterol, and one or more saponins for use as an immunomodulating agent. This matrix, which has the characteristic iscom structure i.e. an open spherical structure having a diameter of about 40 nm formed from annular sub-units having a diameter of about 12 nm, is said to have an adjuvant effect and is intended for use together with one or more antigens. In the same application it is also demonstrated that the saponins in Quil A, an extract from the bark or Quillaja saponaria molina, can be divided into different substances, inter alia B2, B3 and B4b, some of which show adjuvant effect and others a structure giving effect. Morein et al. in Nature, Vol 308, No 5958, p 457-460 (1984) for the first time describe immunostimulating complexes, which are now commonly named iscoms, which have been formed between antigen determinants having hydrophobic areas and glycosides, such as triterpenesaponins and especially Quil A having an adjuvant effect, and which give an immunogenic effect 10-100 times higher than a normal mixture of antigen and Quil A.

It has now surprisingly turned out to be possible to use a particle of the same type as has previously been used as 45 an adjuvant, as a carrier for the administration of drugs. The drug carrying particle in accordance with the invention does not comprise antigen or antigenic determinants and is therefore immunologically inert.

The term adjuvant refers ideally to a substance which can be used for increasing the immunological response to another substance without initiating an immunological response to itself. In addition in this specification

50	matrix = carrier	refers to a structure giving complex between one or more saponins and cholesterol, which in addition optionally also contains other lipids, which can be immunologically inert or immunostimulating depending on the saponins which are included, having the form of spherical nano particles formed by annular subunits,
55	iscom	refers to matrix + antigen, an immunostimulating complex having the same particle structure as the matrix,
	delpha	refers to matrix + drug, a drug carrying particle having the same structure as the matrix.

The present invention comprises a drug carrying particle comprising a structure-giving matrix of a complex of a sterol and one or more saponin components as a carrier to which has been connected a pharmaceutically active sub-

stance which particle has an annular basic structure which can form spherical nano particles, especially of size 30-50 nm characterised in that the saponin components have no adjuvant effect.

According to a preferred aspect the matrix also comprises one or more other lipids, especially phospholipids.

The carrier particles preferably have a size of 30-50 nm, especially about 40 nm.

5 Drug carrier particles according to the invention have the following advantages:

- a narrow particle size distribution, which is of great importance in the administration of a drug in order to obtain a good reproducibility and uniform dosage;
- a sustained duration in the circulation owing to a hydrophilic surface;
- 10 - high stability;
- a possibility to bind amphiphilic and lipophilic pharmaceutical substances which are normally very sparingly soluble and hard to formulate.

It has turned out that a sterol, such as cholesterol, is necessary for the desired matrix to be formed. Useful sterols 15 are in this context those who bind to saponins forming the wanted matrix structure, such as precursors and derivatives of cholesterol, as for example  $\beta$ -sitosterol, stigmasterol and thiocholesterol, the last mentioned of which can especially be used for binding a drug by means of the thiol moiety.

The saponins in question for the formation of complex is every structure forming saponin having hydrophobic areas such as those described in R Tschesche and Wulf, *Chemie Organischer Naturstoffe*, ed. W. Herz, H. Grisebach, G W 20 Kirby, volume 30. (1973). Of special interest are very polar saponins, preferably polar triterpenesaponines such as polar acid bisdesmosides, e g saponin extract from Quillaja bark. Pure saponins without adjuvant effect are especially preferred, such as the substances obtained according to WO 90/03184 from an extract of Quillaja Saponaria Molina having 8-11 carbohydrate groups, i e B4b having a molecular weight of 1862, and optionally B2 having a molecular weight of 1988. The saponin fractions LT 15 and LT 17 have been obtained from the same extract by an alternative method based 25 on a preparative column chromatographic procedure employing similar chromatographic conditions as the thin-layer analytical method described in WO 90/03184.

In addition to the sterol it is of advantage that the matrix comprises one or several other lipids. As example of lipids 30 can be mentioned fats or fatty substances, such as triglycerides or mixed triglycerides containing fatty acids having up to 50 carbon atoms, e g butyric acid, caproic acid, capric acid, caprylic acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid or unsaturated fatty acids having up to 30 carbon atoms such as hexadecenoic acid, unsaturated hydroxy fatty acids; glycerol ethers, waxes, i e esters of higher fatty acids and mono- 35 valent alcohols; phospholipids such as derivatives of glycerolphosphates such as derivatives of phosphatidic acids i e lecithine, cephaline, inositolphosphatides, sphingosine derivatives having 14, 15, 16, 17, 18, 19 or 20 carbon atoms; glycolipids, isoprenoids, sulpholipids, carotenoids, steroids, sterols, cholestanol, caprostanol, phytosterols for instance stigmasterol, sitosterol, myco sterols, for instance ergosterol, bile acids for instance cholic acid, deoxycholic acid, keno-deoxycholic acid, lithocholic acid, steroid glycosides, esters of vitamin A or mixtures thereof. Especially preferred are phospholipids, such as phosphatidylethanolamin, phosphatidylcholin.

It is of course desirable that the starting compounds used for preparing the carrier particles have a toxicity as low 40 as possible. Owing to its stability the matrix which has been formed, however, normally shows a considerably lower toxicity than the sum of the included components.

As mentioned above the structure of delpha is identical to the structure of the matrix. By means of negatively 45 stained electron microscopy an open spherical structure appears, having a diameter of 30-50 nm, especially 35-42 nm, being made up from more or less annular units having a diameter of 10-12 nm. On the enclosed electron micrographs Figures 1, 3 and 6 show different carrier matrices which can be used in accordance with the invention for the administration of pharmaceutically active substances. Figures 2, 4, 5 and 7 show less well defined complexes and Figure 8 shows a defined CoQ<sub>10</sub>-delpha. From this can be seen that all carrier matrices as well as the drug carrying particle show the same regular structure within a fairly narrow size interval.

A typical delpha consists of a cholesterol, one or more saponin components, such as B4b or a mixture of B4b and 50 B2, a pharmaceutically active substance and a lipid, normally a phospholipid. Such a typical delpha having a particle size of 30-50 nm has a molecular ratio saponin: cholesterol: phospholipid: drug of 1:(0.1-10):(0-10):(0.1-50), wherein the saponin quotient consists of 10-100 % B4b and the remainder B2 and optionally other saponines. A normal delpha has a molecular composition of 1:1:0.5:0.5, the saponin being B4b.

For the preparation of a matrix or a delpha having annular particles of the size having a diameter of 10-12 nm the proportion between the different components saponin: cholesterol: phospholipid can be changed.

55 The structure giving matrix used as a carrier, as well as delpha, can be prepared in accordance with WO 90/03184 by solubilisation or transferring into a colloidal form of the sterol in a solvent, addition of the saponin or the saponins and optional additional additives, especially a pharmaceutically active substance, and then the solvent is removed or the concentration is decreased and the complex transferred to a solution in which the components thereof are not soluble, for instance an aqueous solution. This can be done by affinity chromatography, gelfiltration or centrifugation, ultrafiltration,

5 dialyse, electrophoresis or by evaporation of the solvent or by decreasing the concentration of the solvent by dilution. The matrix and delpha, respectively, are then purified from the excess of sterol and saponins for instance by gelfiltration or centrifugation through a density gradient. As solubilizing agent can be used a detergent, such as a nonionic or ionic, such as cathionic or anionic or zwitterionic detergent, such as Zwittergent or a detergent based on bile acid used in excess. Typical examples are mentioned in WO 90/03184 mentioned above. The solubilizing agent is removed at conditions when the pharmaceutically active substance has sufficiently hydrophobic characteristics for being integrated into the delpha complex as formed. Some surfaceactive substances considerably facilitate the formation of the matrix. They comprise biological membrane lipids having a polar main group and a non-polar aliphatic chain, for instance phosphatidylcholine (negatively charged) and phosphatidylethanolamine (positively charged). The solubilizing agent can also be the solvent per se, such as alcohols, organic solvents or small amphiphatic molecules such as heptane-1,2,3-triol, hexane-1,2,3-triol, acetic acid or trifluoro acetic acid. Preferably ethylalcohol, dioxane, ether, chloroform, acetone, benzen, acetic acid, carbon disulfide, MEGA-10 (N-decanoyl-N-methylglucamine) and  $\beta$ -octylglucoside can be used.

10 In general it is necessary to remove the solubilizing agent from the matrix, which for instance can be done by dialysis, ultrafiltration, evaporation or column chromatographical technique. In certain cases it can also be possible after 15 binding of the pharmaceutically active substance in question to dilute the obtained drug carrying particles to a concentration giving a physiologically acceptable solution.

20 The drug carrying particle in accordance with the invention can be prepared by incorporating a pharmaceutically active substance in the carrier matrix by hydrophobic interaction during the formation of the matrix complex as above, but also after the formation of the carrier material. The pharmaceutically active substance can in addition to hydrophobic interaction be linked to the carrier matrix by chemical coupling in a way known per se to a suitable functional group which has been integrated into a previously formed matrix.

25 As an example of functional groups suited for binding the pharmaceutically active substance can be mentioned -NH<sub>2</sub>, -SH, -COOH, -OH. A number of groups and methods of coupling are described in Journal of Immunological Methods, 59 (1983), 129-143, 289-299; in Methods of Enzymology, volume 93, p 280-333; and in Analytical Biochemistry 116, p 402-407 (1981).

30 Pharmaceutically active substances which can be incorporated into a carrier matrix in accordance with the invention may be of varied composition and size. They are either to be incorporated as solitary units or in combination with other molecules. The binding can occur by means of hydrophobic interaction or through a covalent binding. As an example can be mentioned large glycoproteins having a molecular weight of up to 400 kd and oligopeptides with some 35 few amino acids that can be bound by hydrophobic interaction. Also native proteins, triterpenoids and flavines etc can be incorporated through hydrophobic interaction. Certain substances, for instance a number of proteins, poly- and oligopeptides can be incorporated through hydrophobic interaction after the hydrophobic regions having been exposed by various treatments of a denaturing character. Non-hydrophobic molecules can be incorporated into delpha complexes through covalent bindings to incorporated lipophilic components, for instance phosphatidyl-ethanolamine or covalent 40 bindings to sugar, aldehyde etc.

45 The invention also refers to a pharmaceutical composition comprising drug carrying particles as above in combination with a pharmacologically acceptable vehicle. Many conventional pharmaceutical vehicles normally being part in different types of drugs can be used. The delpha particles can for instance be suspended in aqueous solutions or be freeze-dried in the formulations. As example of types of drugs containing delpha the following can be mentioned:

40

- \* injection fluids, injection and infusion substances and implant tablets for parenteral administration.
- \* "solutions", gels, ointments and creams for topical administration.
- \* capsules, tablets, dragées and mixtures for oral administration.

45 The concentration of delpha in the different formulations of drugs may vary depending on the included drugs and the way of administration. Normally 1 ml or 1 g of pharmaceutical formulation may contain 0.01 - 100 mg delpha.

50 The drug carrying particle in accordance with the invention, delpha, can be used in peroral and parenteral administration of pharmaceutical substances. Furthermore, the delpha can be used for topical administration, for instance via the eye, nose and skin, of pharmaceutical substances intended for systemic effect. Also very sparingly soluble pharmaceutical substances can be incorporated into delpha. An example of a substance extremely difficult to dissolve is coenzyme Q<sub>10</sub>, as well as nifedipine, which today are not available on the market as an injection liquids due to their solubility characteristics. There are other substances difficult to dissolve in the groups of corticosteroids and steroid hormones. Furthermore there are certain cytostatics, for instance ethoposide, that are sparingly soluble.

55 Delpha can also be used for parenteral administration of drugs with a short biological half-life. These must be administrated by giving repeated injections, as oral administration is impossible due to enzymatic degradation. A sustained release of said drugs from a delpha particle would make possible fewer injections. As examples of pharmaceutically active substances can be mentioned insulin, growth-hormone, calcitonine, GHRH (growth-hormone-releasing hormone).

Another preferred field of use for the drug carrying particles according to the invention is for parenteral target con-

trolled administration of drugs, especially cytostatica.

In the drug carrying particle, delpha, components may be part of several combinations with different molecules and in this connection it has been shown that the components included have been incorporated by tested cells (macrophages and cells from the cell line Wehei 110). With immunofluorescence and electron microscopy it has been possible 5 to follow the complex into the cell, while micells of the corresponding protein have been disintegrated. Consequently this means that the delpha particles are very stable. The uptake and transportation from the injection site is rapid and the components bound to the carrier matrix according to the invention are transported to different organs, such as for instance draining lymphatic organs. After intraperitoneal administration a comparatively large amount of the components are to be found in the spleen. Other organs are the heart, liver, bile, spleen, kidneys, ureter and urine bladder, 10 lungs. A combination of different components in one and the same particle may imply synergism, as different components may have different tasks; one component may for instance target a certain organ or type of cell or for the penetration of mucous and another component may influence the cell. The components in such a complex can be taken up by one and the same cell which is to be influenced.

The carrier matrix according to the invention, as well as a delpha formed in the same way, is characterized in that 15 neither an antibody mediated immunity (AMI) nor a cell mediated immunity (CMI) is developed against the components included therein. Since no immune response is developed against the carrier matrix it can be used as a carrier for various drugs on repeated occasions without immunological reactions preventing for instance a penetration of mucus in local application in for instance the nose, the conjunctive or per os, or prevent adsorption and further distribution of the carrier or delpha and drugs incorporated therein in the organism in parenteral application. Immunological reactions 20 causing secondary effects can thus be avoided.

For the preparation of a pharmaceutical composition a kit can be provided, comprising separate packages of particles of a structure-giving matrix according to the invention, optionally in combination with a surface-active substance, and a pharmacologically acceptable vehicle.

The invention is furthermore illustrated by the following examples of the preparation and use of a structure giving 25 carrier matrix and drug carrying particles under reference to the enclosed drawings.

Figure 1 shows in a magnification of 200,000 an electron micrograph of a carrier matrix of the invention as prepared in example 2 from Quil A, cholesterol and phosphatidylethanolamine;

30 Figure 2-4 show in a magnification of about 75,000 electron micrographs of three other carrier matrices prepared in accordance with example 3 from Quil A and three different sterols, that is stigmasterol,  $\beta$ -sitosterol and lanosterol;

Figure 5-7 show in a magnification of about 75,000 electron micrographs of three other carrier matrices as prepared in example 4 from Quil A, phosphatidylcholine and one of stigmasterol,  $\beta$ -sitosterol and lanosterol respectively;

35 Figure 8 shows in a magnification of about 75,000 an electron micrograph of delpha particles containing CoQ<sub>10</sub>, prepared in accordance with example 5;

Figure 9 shows in a magnification of about 75,000 an electron micrograph of delpha particles containing amfotericin B, which have been prepared in accordance with example 6 b);

40 Figure 10 refers to the absorbance and counts respectively of different fractions obtained in analysing the delpha particles displayed in figure 9;

Figure 11 shows in a magnification of about 75,000 an electron micrograph of delpha particles containing amfotericin B, which have been prepared in accordance with example 6 d); and

45 Figure 12 refers to the absorbance and counts respectively of different fractions obtained in analysing the delpha particles displayed in figure 11.

In the following examples, No. 1-4 refer to the preparation of carrier particles to which a desired drug can be covalently coupled; No. 5-6 refer to a direct preparation of delpha particles, that is particles wherein a drug has been incorporated into the matrix by hydrophobic interaction; and No. 7-8 refer to the preparation of delpha particles wherein the drug has been covalently coupled to the carrier matrix.

#### 50 Example 1 Delpha carrier

A carrier for non-hydrophobic pharmaceuticals is prepared as follows. 1000  $\mu$ l lipid-mix consisting of 10.0 mg cholesterol (+ traces of <sup>3</sup>H-cholesterol), 10.0 mg phosphatidylethanolamine and 200 mg MEGA-10 (N-decanoyl-N-methyl-amine) in H<sub>2</sub>O are mixed with 500 mg LT15 (a saponin fraction obtained from Karlshamns Lipidteknik AB, Stockholm, Sweden) dissolved in H<sub>2</sub>O (10 % w/w) and the volume is adjusted to 5-10 ml with PBS (0.02 M phosphate buffered saline, 150 mM NaCl, pH 7.4). The mixture is incubated on a shaker for 4-24 hrs before it is dialysed against 5x5 l PBS (ambient temperature for 24-48 hrs., thereafter at +4°C).

The formed carrier complexes are purified from excess material on a sucrose gradient, 10-50 % w/w, 18 hrs.,

5 400,000 rpm (rotor TST 41.14), 10°C. The gradient is emptied from below in 17 fractions which are analysed as to carrier particles ( $^3$ H-cholesterol and electron microscopy, EM) according to the table 1 below. Fractions containing carrier particles are pooled and the exact amount of the included components (cholesterol, phosphatidylethanolamine and saponin) are determined. The carrier particles can for example be concentrated by pelleting (18 hrs., 40,000 rpm (TST 41.14), 10°C). A pelleted carrier is dissolved to a requested concentration of for example 10 mg/ml, in a suitable buffer and is stored at a temperature of +4°C (1 month) or -70°C (long-term storage) until use.

Table 1

	Fraction No.	Cholesterol (cpm)	Particles (EM)
10	1	30	-
15	2	20	-
20	3	27	-
25	4	41	-
30	5	246	+
35	6	11807	+++++
	7	6802	++++
	8	2577	+++
	9	968	++
	10	570	+
	11	471	(+)
	12	329	-
	13	275	-
	14	197	-
	15	139	-
	16	315	-
	17	576	-

The same effect is obtained if LT 15 is replaced by a mixture of LT 15 and LT 17.

40 Example 2 Delpha carriers

45 A carrier for non-hydrophobic pharmaceuticals is prepared as follows. 1000  $\mu$ l lipid-mix, consisting of 10.0 mg cholesterol (+ traces of  $^3$ H-cholesterol), 10.0 mg phosphatidylethanolamine and 200 mg MEGA-10 (N-decanoyl-N-methylglucamine) in H<sub>2</sub>O are mixed with 500 mg Quil A (Spikosid, from Iscotec, Luleå) dissolved in H<sub>2</sub>O (10 % w/w), the volume is adjusted to 5-10 ml with PBS (0.02M phosphate buffered saline, 150 mM NaCl, pH 7.4). The mixture is incubated in shaking for 4-24 hrs before it is dialysed against 5 X 5 l PBS (ambient temperature for 24-48 hrs, thereafter +4°C). The carrier particles can be concentrated, analysed and stored according to example 1. The result of the analyses is given in Table 2 below.

50

55

Table 2

Fraction No.	CPM (3H-cholesterol)	EM (matrix structure)
1	59	
2	54	
3	71	
4	2562	++
5	22801	+++
6	44101	+++
7	17900	+++
8	5717	+++
9	2394	++
10	1471	+
11	970	
12	732	
13	513	
14	676	
15	408	
16	353	
17	690	

Figure 1 shows in a magnification of 200 000 times the carrier matrix of fraction 5, viz. the spherical association complexes of a size of 30-50 nm in diameter, formed from an annular basic structure having a diameter of approximately 10 nm.

The same effect is achieved if instead of Quil A is used 250 mg of each of B2 and B4b, or 500 mg pure B4b.

### Example 3 Delpha carriers

A carrier matrix for non-hydrophobic drugs is manufactured as in example 2 by mixing 100 µl of a solution consisting of 1.0 mg stigmasterol and 20 mg MEGA-10 in H<sub>2</sub>O with 5.0 mg Quil A.

The mixture is incubated on a shaker for 4-24 hrs before it is dialysed against PBS (ambient temperature for 24-48 hrs, thereafter +4°C). The EM verifies that carrier complexes have been formed. Formed complexes are purified on a sucrose gradient 10-50% w/w for 18 hrs at 40 000 rpm (rotor TST 41,14) at 10°C or by sedimentation through 20% w/w sucrose for 18 hrs at 40.000 rpm (rotor TST 41,14) at 10°C. Sedimented complexes are dissolved in PSB. Figure 2 shows in a magnification of 75.000 the obtained basic structure, here as partially associated.

If stigmasterol in the example above is replaced by β-sitosterol monomer carrier particles of an annular basic structure (10-12 nm) is obtained, as is shown in Figure 3. If stigmasterol instead is replaced by lanosterol the basic structure is obtained in another associated form according to Figure 4.

If Quil A in this example is replaced by LT 15 or a mixture of LT 15 and LT 17 similar structures are obtained.

### Example 4 Delpha carriers

A carrier matrix for non-hydrophobic drugs prepared is in accordance with example 2 from 100 µl of a solution consisting of 1.0 mg stigmasterol, 1.0 mg phosphatidylcholine and 20 mg MEGA-10 in H<sub>2</sub>O mixed with 5.0 mg Quil A. The mixture is incubated in a shaker for 4-24 hrs before being dialysed against 5 x 51 PBS (ambient temperature 24-48 hrs, then +4°C). The fact that carrier complexes are formed is verified by EM. Formed complexes are purified on a sucrose gradient 10-20% w/w for 18 hrs at 40,000 rpm (rotor TST 41,14) at 10°C or through/by sedimentation through 20% w/w sucrose for 18 hrs at 40.000 rpm (rotor TST 41,14) at 10°C. Sedimented complexes are dissolved in PBS. Figure 5 shows in a magnification of 75,000 times an electromicrograph of the obtained honeycomb structure.

If, on the other hand, stigmasterol in the above example is replaced by  $\beta$ -sitosterol spherical carrier particles in accordance with Figure 6 are obtained with a structure similar to the one shown in Figure 1. If stigmasterol instead is replaced by lanosterol the main part of the material is precipitated, see Figure 7.

These examples show that from the tested sterols stigmasterol presented the "best" preparation, that is a transparent solution without precipitation in the absence of phospholipid. The lanosterol and the  $\beta$ -sitosterol brought about a lesser precipitation in addition to the complexes shown on the EM photograph. When phospholipid was added the solution with lanosterol and stigmasterol, respectively, became opalescent, which indicates that a great part of the material did not form any complex with Quil A.  $\beta$ -sitosterol on the other hand formed a well-defined matrix with Quil A and phospholipid.

10 Example 5 CoQ<sub>10</sub> -delpha

2 mg CoQ<sub>10</sub> are dissolved in about 25  $\mu$ l chloroform and mixed with a 400  $\mu$ l lipid-mix, consisting of 4.0 mg cholesterol (+ traces of <sup>3</sup>H-cholesterol), 4.0 mg phosphatidylcholine and 80 mg MEGA-10 in H<sub>2</sub>O. The chloroform is evaporated by a gentle nitrogen bubbling while vigorous stirring of the mixture. The temperature is kept at 25-35°C. When the chloroform has been removed 10 mg Quil A (Spikosid) dissolved in H<sub>2</sub>O (10% w/w) is added, the volume is adjusted to 2 ml with PBS [phosphate-buffered (0.02M), 150mM NaCl, pH 8.4]. The mixture is incubated in shaking for 2-4 hrs (in darkness), before being dialysed against 3 X 5 l PBS (in darkness, ambient temperature).

25 The formed CoQ<sub>10</sub>-carrying particles are purified from excess material on a sucrose gradient, 10-50% w/w, 18 hrs, 40.000 rpm TST 41,14), 10°C. The gradient is emptied from below in 17 fractions which is each analysed as to the CoQ<sub>10</sub> (A330) and delpha particles (<sup>3</sup>H-cholesterol and electron microscopy). Fractions containing CoQ<sub>10</sub>-delpha are pooled and the exact concentration of CoQ<sub>10</sub> is determined. <sup>3</sup>H-cholesterol is determined by taking 50  $\mu$ l samples from each fraction in the gradient, mixing with 4 ml scintillation fluid (optiphase Hisafe II, Pharmacia-LKB) and counting for 60 seconds in a  $\beta$ -counter (Rackbeta, LKB). The result is shown in Table 3 below.

Table 3

	Fract. No.	CPM (3H-cholesterol)	A330 (CoQ <sub>10</sub> )	EM (matrix structure)
30	1	22	0.055	-
	2	23	0.056	-
	3	32	0.053	-
	4	30	0.081	-
35	5	25	0.080	-
	6	1410	0.149	+
	7	12120	0.653	+++
	8	9624	0.397	+++
40	9	3600	0.167	++
	10	1513	0.124	+
	11	1578	0.289	+
	12	1023	0.382	(+)
45	13	507	0.357	-
	14	408	0.213	-
	15	437	0.384	-
	16	275	0.499	-
50	17	294	1.225	-

55

Figure 8 shows in a magnification of 1:75,000 an electron micrograph of the delpha structure obtained in fraction 7, 30-50 nm, similar to the photograph in Figure 1.

The same result is obtained if instead of Quil A 5 mg of each of B2 and B4b are used.

Example 6 Amfotericin B delpha

In order to prepare amfotericin B delpha particles 1 mg amfotericin B was dissolved in 75  $\mu$ l DMSO and mixed with

5 a) 2 mg of each of cholesterol and phosphatidyl choline and mixed with 10 mg B4b (LT 15);  
 b) 3 mg of each of cholesterol and phosphatidyl choline and mixed with 15 mg B4b (LT 15);  
 c) 2 mg of each of cholesterol and phosphatidyl choline and mixed with 8 mg B4b (LT 15) and 2 mg B2 (LT 17); or  
 d) 3 mg of each of cholesterol and phosphatidyl choline and mixed with 12 mg B4b (LT 15) and 3 mg B2 (LT 17);

10 in a volume of 1 ml PBS. The complexes were made and analyzed as described in example 1.

The fractions obtained from sucrose density gradient centrifugation were analyzed for cholesterol (cpm), absorbance at 405 nm (amfotericin B) and structure (EM) and showed that amfotericin B efficiently incorporated into delpha particles. The use of only LT 15 and amfotericin B produces a somewhat aggregated delpha, an addition of LT 17 helped to give non-aggregated particles.

15 Figure 9 shows an electron micrograph of amfotericin B delpha particles prepared according to method b) above in a magnification of about 75,000;

Figure 10 shows a graph of the absorbance and counts respectively obtained from the analysis of the different fractions obtained from the amfotericin B delpha particles prepared according to said method b);

20 Figure 11 shows an electron micrograph of amfotericin B delpha particles prepared according to method d) above in a magnification of about 75,000;

Figure 12 shows a graph of the absorbance and count respectively obtained from the analysis of the different fractions obtained from the amfotericin B delpha particles prepared according to said method d).

A larger proportion of LT 17 will give an increased amount of sub units (10-12 nm), which on the graph in figure 12 can be seen as a second peak.

25

Example 7 LHRH-delpha

LHRH (luteinizing hormone releasing hormone) is conjugated to the carrier matrix in accordance with the principles for conjugation via cysteine by means of maleidohexanoyl-N-hydroxysuccinimidester (MHS), described by Lee et al ,  
 30 Molecular Immunology, Vol. 17, pages 749-756 (1980).

The peptide is reduced according to the following. 1 mg peptide is dissolved in 400  $\mu$ l 0.1 M sodiumphosphate buffer pH 8.0. A 250 x molar excess of dithiotreitol (DTT) is added and the mixture is incubated at ambient temperature for 30-60 minutes. The peptide is separated from DTT by gelfiltration on Sephadex G-10 (Pharmacia, Uppsala) equilibrated with deaired  $N_2$ saturated 0.1 M sodiumphosphate buffer pH 6.66, containing 0.1 M EDTA.

35 The carrier matrix according to example 2 is MHS modified as follows: 2.0 mg carrier in 450  $\mu$ l 0.1 M sodiumphosphate buffer, pH 6.66, is mixed with 10-100 x molar excess of MHS (in 50  $\mu$ l DMSO) to phosphatidylethanolamine in the matrix. The reaction mixture is stirred gently at ambient temperature for 1 hour. Excess of MHS and other reaction products are removed through gelfiltration at Sephadex G-25 (Pharmacia, Uppsala) equilibrated with deaired  $N_2$ saturated 0.1 M sodiumphosphate buffer pH 6.66, containing 0.1 M EDTA. The solution with reduced peptide is mixed with MHS  
 40 activated carrier in a 5 x molar excess ratio of peptides to phosphatidylethanolamine. The conjugation is allowed to continue during stirring for 18-24 hours.

45 LHRH-delpha is purified from excess material on a sucrose gradient, 10-50% w/w, 18 hrs, 40.000 rpm (TST 41.14), 10°C. The gradient is emptied from below in 17 fractions which each is analysed as to LHRH and delpha particles ( $^3$ H-cholesterol and electron microscopy). Fractions containing LHRH-delpha particles are pooled and the concentration is determined.

Example 8 Biotin-delpha

50 1 mg (2.0 mg/ml) carrier (made according to example 2) in 0.1 M carbonate buffer, pH 8.8, is mixed with N-hydroxysuccinimidebiotin (10 mg/ml in DMSO) in an excess of 10 X 1 in relation to phosphatidylethanolamine. The mixture is incubated for 15 minutes at ambient temperature. The biotin-delpha-particles are purified from surplus material on a sucrose gradient, 10-50% w/w, 18 hrs, 40,000 rpm (TST 41.14), 10°C. The gradient is emptied from below in 17 fractions which each is analysed as to LHRH and delpha particles ( $^3$ H-cholesterol and electronmicroscopy), see Table 4 below, and biotin. Fractions containing biotin-delpha particles are pooled and the quantity is determined.

55

Table 4

Fract. No.	CPM (3H-cholesterol)	EM (matrix structure)
1	45	-
2	22	-
3	41	-
4	24	-
5	1314	+
6	14993	++
7	26315	+++
8	8239	++
9	3644	++
10	1704	+
11	1024	
12	673	
13	523	
14	321	
15	230	
16	170	
17	154	

30 A pool consisting of the fractions 5-10 is analyzed for biotin in an ELISA.

35 Coat: mouse anti-biotin (monoclonal) 10 g/ml in a 50 mM carbonate buffer, pH 9.6, 4°C over night.

Dilution tests (pool and non-biotinylated matrix):

1/50, 1/150, 1/450 etc in PBS Tween (0.05%), 1 hr, ambient temperature, on a shaker.

Conjugate: avidine-HRP (horse-radish peroxidase) 1/2000 in PBS Tween (0.05%), 1 h, ambient temperature, on a shaker.

Development: TMB (tetramethyl benzidine) 0.10 mg/ml and H<sub>2</sub>O<sub>2</sub> (0.006%) in 0.1 M acetate, pH 6.0.

Table 5

Dilution test	ABS (pool)	ABS (control matrix)
1/50	1.997	0.097
1/150	2.107	0.078
1/450	1.874	0.106
1/1350	1.201	0.099
1/4050	1.816	0.100
1/12150	0.206	0.089
1/36450	0.096	0.090
1/109350	0.103	0.115

55 The following test shows the distribution of drug in the body after administration by means of a delpha according to

the invention.

Biological tests to show that the carrier is immunologically inert

5 **LT 15**

LT 15 is an adjuvant depleted fraction of Quil A which has been obtained from Karlshamns Lipidteknik AB.

A conventional saponin adjuvant, like Quil A, potentiates the immune response to an antigen when mixed with the antigen prior to e.g. subcutaneous injection. To confirm that LT 15 (which is very similar to the B4b preparation) is 10 depleted of adjuvant active saponins the following test for adjuvant activity was performed in mice.

3 groups of 5 mice were immunized with 1  $\mu$  g of protein micelles made from influenza virus glycoproteins (Lövgren et al 1987) plus:

15 a) 10  $\mu$  g LT 15  
 b) 10  $\mu$  g Quil A  
 c) saline

Two weeks after immunization the mice were bled and the serum was assayed for antibodies to the viral proteins (standard Elisa technique employing microtine plates coated with the antigen and a commercial enzyme-conjugated rabbit 20 anti-mouse preparation for detection of mouse immunoglobulins). The result shown in table 6 below demonstrates that LT 15 as well as plain saline did not potentiate the antibody response to the protein micelles in contrast to the non-depleted Quil A preparation.

25

Table 6

Group	Amount of antibody (arbitrary unit)
a)	714±397
b)	1055±347
c)	800±367

35 **Different biotin-carriers**

The administration of biotin to mouse using different carriers. In order to verify that the carrier matrix is immunologically inert when used as a drug carrier a comparative test was made with biotin administered as biotin-delpha and with immunologically active carriers. Mice were injected subcutaneously with biotin carried by immunologically active carriers - iscom and micelle respectively - containing surface proteins from an influenza virus. After an immunization with 3 40  $\mu$ g carrier-biotin all mice had high (iscom) or medium high (micelle) serum titres against biotin. Eight weeks later the mice were given a "booster-dose" with biotin-delpha-particles. Two weeks later serum samples were taken and the amount of antibodies against biotin before and after the administration of the biotin-delpha was compared. A control group of animals was injected with biotin-delpha on both occasions. As appears from Table 7, the administration of biotin-delpha had no effect on the antibody response against biotin not even in those cases when the animals had been 45 primarily immunized against biotin linked to an immunologically active carrier. After a booster with an active carrier the serum titres against biotin were increased 5-10 times (not shown in Table 7).

Table 7

Primary administration		Secondary administration	
biotin-formulation	antibody response against biotin	biotin-formulation	antibody response against biotin
biotin-iscom (33 mice)	2999±467 (1824 - 3781)	biotin-delpha (11 mice)	3101±317 (2301 -3476)
biotin-micelle (33 mice)	973±470 (291±1971)	biotin-delpha (11 mice)	850-486 (398 -1978)
biotin-delpha (34 mice)	59±13 (42-89)	biotin-delpha (11 mice)	49±5 (42-57)

Autoradiography of CoQ<sub>10</sub>-delpha in mouse

5 Delpha-particles were prepared by 1 mg CoQ<sub>10</sub>, 2 mg <sup>3</sup>H-cholesterol, 2 mg phosphatidylcholin, 10 mg MEGA-10 and 10 mg LT 15 in a volume of 1 ml H<sub>2</sub>O according to example 5. The fractions 5-7 were pooled and the content of cholesterol was determined by means of the <sup>3</sup>H-activity to be 0.73 mg cholesterol/ml. The content of CoQ<sub>10</sub> was estimated to ≤ 0.1 mg/ml.

10 4 female mice were injected subcutaneously in the neck with 0.4 ml of the mixture above. The mice were sacrificed and sectioned for autoradiography after 15 min, 2 h, 6 h and 24 h.

15 After 24 h particles were still present at the site of injection, which indicates that the cholesterol is linked to the particles. Compared with administration of free cholesterol high levels of cholesterol were found in the liver and in the blood; still more in the lungs; and still more in the spleen, bone marrow and local lymphatic organs. It was observed that the level in the blood increased continuously up to 24 h.

20 From this can be concluded that the cholesterol mainly is particle-bonded; if pure cholesterol is injected there will be a concentration of cholesterol in the adrenal cortex.

Administration of CoQ<sub>10</sub> to mouse

25 The length of the isoprene chain in the Coenzyme Q (CoQ) varies in different animal species. CoQ<sub>9</sub> thus contains 9 isoprene units in the chain and CoQ<sub>10</sub> contains 10 units. Man only produces CoQ<sub>10</sub> whereas the rat and mouse produce about 95% CoQ<sub>9</sub> and 5% of CoQ<sub>10</sub>. Due to the low endogene concentration of CoQ<sub>10</sub> mouse was chosen as for the experiment in the following test:

30 15 NMRI mice (females) 19.20g ± 0.90 g were injected subcutaneously with 14.6 µg CoQ<sub>10</sub>-delpha (0.8 mg/kg) made with B2 + B4b instead of Quil A according to example 5, i.e. with 0.2 ml of a formulation containing 73 µg/ml CoQ<sub>10</sub>. At T = 0, 0.5, 1, 3, 5 and 8 hours blood samples were taken and at T = 0, 0.5, 3 and 8 hours organs were also removed (heart, liver, kidneys and spleen). To measure the endogene level a control group of 6 (mice) were injected with empty delpha complexes, i.e. only carriers in a corresponding amount. Blood samples and organs were taken from this control group at T = 0.5 and 7 hours. As a comparison serum and organs were taken also from 3 non treated mice. The blood was centrifuged and plasma and organs were kept at a temperature of -20°C until analysed. The chemical analyses of CoQ<sub>10</sub> were carried out with liquid chromatography in accordance with a method described by P-O Englund in J. Chromatogr. 425 (1988), 87-97. The organ samples were homogenised with a Potter-S homogenisator in 10 volumes 1-propane containing an intern standard. The liquid phase was injected into the liquid chromatograph. The chemical analyses showed an increase of the CoQ<sub>10</sub> content in serum and heart, see table 8. To analyse cholesterol a sample, 1 ml, from the liquid phase is mixed with 8 ml scintillation fluid (Orphphase Hisafe II, Pharmacia LKB) and is counted for 2000 seconds in a β-counter (Rackbeta, LKB). In measuring the radioactivity in the organ samples (<sup>3</sup>H-cholesterol) a distinct radioactivity was registered only in liver samples.

35 The following can be concluded from the experiment:

- 40 \* since the CoQ<sub>10</sub> part is continuously increased in serum for 8 hours, and probably longer, the delpha complexes have not immediately been eliminated by RES
- \* the delpha-complex is supposed to have delivered CoQ<sub>10</sub> to the heart as CoQ<sub>10</sub> in the heart tends to increase without a corresponding increase of the cholesterol of the complexes being found
- \* the delpha complexes and/or included cholesterol are likely to be eliminated via the liver which demonstrated the highest degree of radioactivity.

45

50

55

Table 8

	Mouse No	Time h	Spleen µg/g	Kidney µg/g	Liver µg/g	Heart µg/g	Serum µg/ml
5	1 (contr.)	0.5	6.770	11.500	3.050	21.000	0.034
	2 (contr.)	0.5	7.100	10.900	2.610	40.800	0.054
	3 (contr.)	0.5	6.820	9.760	3.050	21.300	0.031
10	4 (contr.)	7.0	6.620	11.800	5.160	11.200	0.041
	5 (contr.)	7.0	7.040	13.500	2.790	11.400	0.033
	6 (contr.)	7.0	8.020	11.100	2.410	10.100	0.015
15	7 non treated	-	7.970	10.500	3.830	47.400	0.045
	8 non treated	-	7.270	11.400	2.780	10.800	0.022
	9 non treated	-	7.250	10.600	3.000	44.700	0.020
20	10	0.5	7.300	11.500	3.240	12.300	
	11	0.5	8.270	12.300	3.440	45.100	0.019
	12	0.5	6.560	10.500	2.730	11.800	0.030
25	13	1.0	7.880	10.600	3.360	11.300	0.048
	14	1.0	7.300	11.200	3.110	9.520	0.060
	15	1.0	7.350	10.700	3.850	40.200	0.019
30	16	3.0	8.130	10.800	2.900	47.600	0.195
	17	3.0	8.340	11.000	2.870	45.400	0.184
	18	3.0	7.060	11.300	3.150	37.800	0.131
35	19	5.0	8.200	11.100	3.070	49.900	
	20	5.0	7.240	11.100	3.950	46.700	0.186
	21	5.0	7.140	9.950	3.740	41.300	0.247
40	22	8.0	8.090	11.600	4.020	40.600	0.206
	23	8.0	8.770	11.800	3.380	44.600	0.266
	24	8.0	7.120	11.800	2.720	47.800	0.203

## Claims

45 1. Drug carrying particle comprising a structure-giving matrix of a complex of a sterol and one or more saponin components as a carrier to which has been connected a pharmaceutically active substance which particle has an annular basic structure which can form spherical nano particles, especially of size 30-50 nm characterised in that the saponin components have no adjuvant effect.

50 2. Drug carrying particle according to claim 1, characterised in that the matrix also comprises one or more other lipids, especially phospholipids.

55 3. Drug carrying particle according to claim 1 or 2, characterised in that the spherical particle has a size of 35-42 nm.

4. Drug carrying particle according to claim 3, characterised in that the spherical particle has a size of about 40 nm.

5. Drug carrying particle according to any preceding claim characterised in that the sterol is cholesterol.

6. Drug carrying particle according to any preceding claim characterised in that the saponin component is one or more of the saponins B4b, B2, LT15 or LT17.
- 5 7. Drug carrying particle according to any of claims 1-6, characterised in that the matrix is formed from cholesterol and the saponin B4b or LT 15, optionally in combination with the saponin B2 or LT17, and in addition comprises a phospholipid.
- 10 8. Drug carrying particle according to any of claims 2-7, characterised in that the phospholipid is phosphatidylethanolamine or phosphatidylcholine.
- 15 9. Drug carrying particle according to any of claims 1-8, characterised in that the pharmaceutically active substance has been connected to the matrix by covalent or hydrophobic bonds.
10. Drug carrying particle according to any of claims 1-9, characterised in that the pharmaceutically active substance is CoQ<sub>10</sub>.
- 15 11. Drug carrying particle according to any of claims 1-9, characterised in that the pharmaceutically active substance is amfotericin B.
- 20 12. A pharmaceutical composition comprising drug carrying particles according to any of claims 1-11 in combination with a pharmacologically acceptable vehicle.
13. A pharmaceutical composition according to claim 12, adapted for oral administration.
- 25 14. A pharmaceutical composition according to claim 12, adapted for parenteral administration.
15. A pharmaceutical composition according to claim 12, adapted for topical administration.
- 30 16. Drug carrying particle according to any of claims 1-11, for use in therapy.

30 Patentansprüche

1. Arzneimitteltragendes Teilchen, umfassend eine strukturgebende Matrix aus einem Komplex aus einem Sterol und einer oder mehreren Saponinkomponenten als Träger, mit dem eine pharmazeutisch aktive Substanz verbunden ist, wobei das Teilchen eine ringförmige Basisstruktur besitzt, die sphärische Nanoteilchen insbesondere mit einer Größe von 30 bis 50 nm bilden kann, dadurch gekennzeichnet, daß die Saponinkomponenten keine Adjuvanswirkung besitzen.
- 35 2. Arzneimitteltragendes Teilchen nach Anspruch 1, dadurch gekennzeichnet, daß die Matrix auch ein oder mehrere andere Lipide, insbesondere Phospholipide, umfaßt.
3. Arzneimitteltragendes Teilchen nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das sphärische Teilchen eine Größe von 35 bis 42 nm besitzt.
- 45 4. Arzneimitteltragendes Teilchen nach Anspruch 3, dadurch gekennzeichnet, daß das sphärische Teilchen eine Größe von etwa 40 nm besitzt.
5. Arzneimitteltragendes Teilchen nach einem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß das Sterol Cholesterin ist.
- 50 6. Arzneimitteltragendes Teilchen nach einem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß die Saponinkomponente ein oder mehrere der Saponine B4b, B2, LT15 oder LT17 ist.
7. Arzneimitteltragendes Teilchen nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, daß die Matrix gebildet ist aus Cholesterin und dem Saponin B4b oder LT15, gegebenenfalls in Kombination mit Saponin B2 oder LT17 und zusätzlich ein Phospholipid umfaßt.
- 55 8. Arzneimitteltragendes Teilchen nach einem der Ansprüche 2 bis 7, dadurch gekennzeichnet, daß das Phospholipid Phosphatidylethanolamin oder Phosphatidylcholin ist.

9. Arzneimitteltragendes Teilchen nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß die pharmazeutisch aktive Substanz mit der Matrix durch kovalente oder hydrophobe Bindungen verbunden ist.

5 10. Arzneimitteltragendes Teilchen nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß die pharmazeutisch aktive Substanz CoQ<sub>10</sub> ist.

11. Arzneimitteltragendes Teilchen nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß die pharmazeutisch aktive Substanz Amfotericin B ist.

10 12. Pharmazeutisches Mittel umfassend arzneimitteltragende Teilchen nach einem der Ansprüche 1 bis 11 in Kombination mit einem pharmakologisch annehmbaren Hilfsmittel.

13. Pharmazeutisches Mittel nach Anspruch 12, adaptiert für orale Verabreichung.

15 14. Pharmazeutisches Mittel nach Anspruch 12, adaptiert für parenterale Verabreichung.

15. Pharmazeutisches Mittel nach Anspruch 12, adaptiert für topische Verabreichung.

16. Arzneimittelhaltiges Teilchen nach einem der Ansprüche 1 bis 11 zur Verwendung bei der Therapie.

20 **Revendications**

1. Particule supportant un médicament comprenant une matrice structurante d'un complexe d'un stérol et d'un ou plusieurs composant(s) saponine(s) en tant que support à laquelle a été fixée une substance pharmaceutiquement active, ladite particule possédant une structure de base annulaire qui peut former des nanoparticules sphériques, particulièrement de dimension 30-50 nm, caractérisée en ce que les composants saponines n'ont aucun effet adjuvant.

25 2. Particule supportant un médicament selon la revendication 1, caractérisée en ce que la matrice comprend également un ou plusieurs autres lipides, particulièrement des phospholipides.

30 3. Particule supportant un médicament selon la revendication 1 ou 2, caractérisée en ce que la particule sphérique a une dimension de 35-42 nm.

35 4. Particule supportant un médicament selon la revendication 3, caractérisée en ce que la particule sphérique a une dimension d'environ 40 nm.

5. Particule supportant un médicament selon l'une quelconque des revendications précédentes caractérisée en ce que le stérol est le cholestérol.

40 6. Particule supportant un médicament selon l'une quelconque des revendications précédentes caractérisée en ce que le composant saponine est au moins une des saponines B4b, B2, LT15 ou LT17.

7. Particule supportant un médicament selon l'une quelconque des revendications 1-6, caractérisée en ce que la matrice est formée à partir de cholestérol et de la saponine B4b ou LT15, éventuellement en combinaison avec la saponine B2 ou LT17, et comprend en outre un phospholipide.

45 8. Particule supportant un médicament selon l'une quelconque des revendications 2-7, caractérisée en ce que le phospholipide est la phosphatidyléthanolamine ou la phosphatidylcholine.

50 9. Particule supportant un médicament selon l'une quelconque des revendications 1-8, caractérisée en ce que la substance pharmaceutiquement active a été fixée à la matrice par des liaisons covalentes ou hydrophobes.

10. Particule supportant un médicament selon l'une quelconque des revendications 1-9, caractérisée en ce que la substance pharmaceutiquement active est CoQ<sub>10</sub>.

55 11. Particule supportant un médicament selon l'une quelconque des revendications 1-9, caractérisée en ce que la substance pharmaceutiquement active est l'amphotéricine B.

12. Composition pharmaceutique comprenant des particules supportant un médicament selon l'une quelconque des revendications 1-11 en combinaison avec un véhicule pharmacologiquement acceptable.
13. Composition pharmaceutique selon la revendication 12, adaptée pour une administration orale.
- 5 14. Composition pharmaceutique selon la revendication 12, adaptée pour une administration parentérale.
15. Composition pharmaceutique selon la revendication 12, adaptée pour une administration topique.
- 10 16. Particule supportant un médicament selon l'une quelconque des revendications 1-11, pour une utilisation en thérapie.

15

20

25

30

35

40

45

50

55




Fig. 1

Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7



EP 0 587 659 B1




Fig. 8

Fig. 10

**b**





Fig. 9

Fig. 12




Fig. 11

